Trial reportJournal of the National Cancer Institute2018
Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30.
Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
In one paragraph
Trial report in Journal of the National Cancer Institute, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04558034 (The Use of Cryotherapy to Prevent Paclitaxel-induced Peripheral Neuropathy and Nail Changes in Women With Breast Cancer), which is not on this map. Cited by 74 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 4 pooled it
3.9field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Use of Cryotherapy to Prevent Paclitaxel-induced Peripheral Neuropathy and Nail Changes in Women With Breast Cancer
Who cites it
74 citing papers in PubMed, 4 syntheses or guidelines pooled it, 126 citations in OpenAlex.
- Coasting related to taxane-induced peripheral neuropathy in patients with breast cancer: a systematic review.Acta oncologica (Stockholm, Sweden) · 2025Pooled it
- The Association Between the Incidence Risk of Peripheral Neuropathy and PD-1/PD-L1 Inhibitors in the Treatment for Solid Tumor Patients: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2019Pooled it
- Chemotherapy-Associated Peripheral Neuropathy in Patients With Early-Stage Breast Cancer: A Systematic Review.Journal of the National Cancer Institute · 2018Pooled it
- Incidence and influencing factors of chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review and meta-analysis.Frontiers in neurologyPooled it
- Bilateral transcutaneous auricular vagus nerve stimulation for the treatment of insomnia in breast cancer.Scientific reports · 2025Trial
- Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Trial
- Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Trial
- Trial
- Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- Acupuncture for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Survivors: A Randomized Controlled Pilot Trial.The oncologist · 2020Trial
- MammaPrint guides treatment decisions in breast Cancer: results of the IMPACt trial.BMC cancer · 2020Trial
- Efficacy of Exercise on Severity of Paclitaxel-Induced Peripheral Neuropathy and Improving Quality of Life in Women with Non-metastatic Breast Cancer: Results of an Interim Analysis from an Ongoing Randomized Clinical Trial (ExPIN Trial).Integrative cancer therapiesTrial
- Prevalence and factors associated with chemotherapy induced peripheral neuropathy among adult patients with cancer at Mbarara Regional Cancer Centre: a cross-sectional study.BMC neurology · 2026Article
- Long-term chemotherapy-induced peripheral neuropathy evaluated using patient-reported outcomes in gynecologic malignancies.Journal of gynecologic oncology · 2026Article
- Risk Prediction Model for Taxane-Induced Peripheral Neuropathy in Early-Stage Cancer.JAMA network open · 2026Observational
- A phase II randomized placebo-controlled study of fisetin to improve physical function in breast cancer survivors: the TROFFi study rationale and trial design.Therapeutic advances in medical oncology · 2026Article
- Chemotherapy-induced peripheral neuropathy in patients with breast cancer treated with taxanes (Review).Oncology letters · 2025Review
- Analyses of adverse events and patient-reported outcomes with the toxicity index in cancer clinical trials.Cancer · 2025Review
- Article
- Addressing the Needs of Breast Cancer Survivors.Current oncology reports · 2025Review
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 10 institutions in 2 countries.
Hanna BandosNRG Oncology and The University of Pittsburgh, Pittsburgh, PA; Center for Healthcare Policy and Research, University of California Davis, Sacramento, CA; Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD; NRG Oncology and The Washington Cancer Institute at Washington Hospital Center, Washington, DC and current: Georgetown University, Washington, DC; NRG Oncology and The Colorado Cancer Research Program, Denver, CO; NRG Oncology and Kaiser Permanente, Northern California, Vallejo, CA; NRG Oncology and The Central Illinois CCOP Heartland NCORP, Decatur, IL; NRG Oncology and The University of Pittsburgh/Magee Womens Hospital, Pittsburgh, PA; NRG Oncology and The Allegheny Health Network, Pittsburgh, PA; NRG Oncology and The Jewish General Hospital, McGill University, Montréal, QC, Canada; NRG Oncology and The MedStar Franklin Square Medical Center/Harry and Jeanette Weinberg Cancer Institute, Baltimore, MD; NRG Oncology and The University of California Los Angeles, Schools of Medicine and Public Health, Los Angeles, CA; Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, CA.
Joy MelnikowNRG Oncology and The University of Pittsburgh, Pittsburgh, PA; Center for Healthcare Policy and Research, University of California Davis, Sacramento, CA; Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD; NRG Oncology and The Washington Cancer Institute at Washington Hospital Center, Washington, DC and current: Georgetown University, Washington, DC; NRG Oncology and The Colorado Cancer Research Program, Denver, CO; NRG Oncology and Kaiser Permanente, Northern California, Vallejo, CA; NRG Oncology and The Central Illinois CCOP Heartland NCORP, Decatur, IL; NRG Oncology and The University of Pittsburgh/Magee Womens Hospital, Pittsburgh, PA; NRG Oncology and The Allegheny Health Network, Pittsburgh, PA; NRG Oncology and The Jewish General Hospital, McGill University, Montréal, QC, Canada; NRG Oncology and The MedStar Franklin Square Medical Center/Harry and Jeanette Weinberg Cancer Institute, Baltimore, MD; NRG Oncology and The University of California Los Angeles, Schools of Medicine and Public Health, Los Angeles, CA; Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, CA.
Donna R RiveraNRG Oncology and The University of Pittsburgh, Pittsburgh, PA; Center for Healthcare Policy and Research, University of California Davis, Sacramento, CA; Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD; NRG Oncology and The Washington Cancer Institute at Washington Hospital Center, Washington, DC and current: Georgetown University, Washington, DC; NRG Oncology and The Colorado Cancer Research Program, Denver, CO; NRG Oncology and Kaiser Permanente, Northern California, Vallejo, CA; NRG Oncology and The Central Illinois CCOP Heartland NCORP, Decatur, IL; NRG Oncology and The University of Pittsburgh/Magee Womens Hospital, Pittsburgh, PA; NRG Oncology and The Allegheny Health Network, Pittsburgh, PA; NRG Oncology and The Jewish General Hospital, McGill University, Montréal, QC, Canada; NRG Oncology and The MedStar Franklin Square Medical Center/Harry and Jeanette Weinberg Cancer Institute, Baltimore, MD; NRG Oncology and The University of California Los Angeles, Schools of Medicine and Public Health, Los Angeles, CA; Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, CA.
Sandra M SwainNRG Oncology and The University of Pittsburgh, Pittsburgh, PA; Center for Healthcare Policy and Research, University of California Davis, Sacramento, CA; Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD; NRG Oncology and The Washington Cancer Institute at Washington Hospital Center, Washington, DC and current: Georgetown University, Washington, DC; NRG Oncology and The Colorado Cancer Research Program, Denver, CO; NRG Oncology and Kaiser Permanente, Northern California, Vallejo, CA; NRG Oncology and The Central Illinois CCOP Heartland NCORP, Decatur, IL; NRG Oncology and The University of Pittsburgh/Magee Womens Hospital, Pittsburgh, PA; NRG Oncology and The Allegheny Health Network, Pittsburgh, PA; NRG Oncology and The Jewish General Hospital, McGill University, Montréal, QC, Canada; NRG Oncology and The MedStar Franklin Square Medical Center/Harry and Jeanette Weinberg Cancer Institute, Baltimore, MD; NRG Oncology and The University of California Los Angeles, Schools of Medicine and Public Health, Los Angeles, CA; Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, CA.
Keren SturtzNRG Oncology and The University of Pittsburgh, Pittsburgh, PA; Center for Healthcare Policy and Research, University of California Davis, Sacramento, CA; Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD; NRG Oncology and The Washington Cancer Institute at Washington Hospital Center, Washington, DC and current: Georgetown University, Washington, DC; NRG Oncology and The Colorado Cancer Research Program, Denver, CO; NRG Oncology and Kaiser Permanente, Northern California, Vallejo, CA; NRG Oncology and The Central Illinois CCOP Heartland NCORP, Decatur, IL; NRG Oncology and The University of Pittsburgh/Magee Womens Hospital, Pittsburgh, PA; NRG Oncology and The Allegheny Health Network, Pittsburgh, PA; NRG Oncology and The Jewish General Hospital, McGill University, Montréal, QC, Canada; NRG Oncology and The MedStar Franklin Square Medical Center/Harry and Jeanette Weinberg Cancer Institute, Baltimore, MD; NRG Oncology and The University of California Los Angeles, Schools of Medicine and Public Health, Los Angeles, CA; Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, CA.
Louis FehrenbacherNRG Oncology and The University of Pittsburgh, Pittsburgh, PA; Center for Healthcare Policy and Research, University of California Davis, Sacramento, CA; Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD; NRG Oncology and The Washington Cancer Institute at Washington Hospital Center, Washington, DC and current: Georgetown University, Washington, DC; NRG Oncology and The Colorado Cancer Research Program, Denver, CO; NRG Oncology and Kaiser Permanente, Northern California, Vallejo, CA; NRG Oncology and The Central Illinois CCOP Heartland NCORP, Decatur, IL; NRG Oncology and The University of Pittsburgh/Magee Womens Hospital, Pittsburgh, PA; NRG Oncology and The Allegheny Health Network, Pittsburgh, PA; NRG Oncology and The Jewish General Hospital, McGill University, Montréal, QC, Canada; NRG Oncology and The MedStar Franklin Square Medical Center/Harry and Jeanette Weinberg Cancer Institute, Baltimore, MD; NRG Oncology and The University of California Los Angeles, Schools of Medicine and Public Health, Los Angeles, CA; Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, CA.
James L WadeNRG Oncology and The University of Pittsburgh, Pittsburgh, PA; Center for Healthcare Policy and Research, University of California Davis, Sacramento, CA; Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD; NRG Oncology and The Washington Cancer Institute at Washington Hospital Center, Washington, DC and current: Georgetown University, Washington, DC; NRG Oncology and The Colorado Cancer Research Program, Denver, CO; NRG Oncology and Kaiser Permanente, Northern California, Vallejo, CA; NRG Oncology and The Central Illinois CCOP Heartland NCORP, Decatur, IL; NRG Oncology and The University of Pittsburgh/Magee Womens Hospital, Pittsburgh, PA; NRG Oncology and The Allegheny Health Network, Pittsburgh, PA; NRG Oncology and The Jewish General Hospital, McGill University, Montréal, QC, Canada; NRG Oncology and The MedStar Franklin Square Medical Center/Harry and Jeanette Weinberg Cancer Institute, Baltimore, MD; NRG Oncology and The University of California Los Angeles, Schools of Medicine and Public Health, Los Angeles, CA; Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, CA.
Adam M BrufskyNRG Oncology and The University of Pittsburgh, Pittsburgh, PA; Center for Healthcare Policy and Research, University of California Davis, Sacramento, CA; Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD; NRG Oncology and The Washington Cancer Institute at Washington Hospital Center, Washington, DC and current: Georgetown University, Washington, DC; NRG Oncology and The Colorado Cancer Research Program, Denver, CO; NRG Oncology and Kaiser Permanente, Northern California, Vallejo, CA; NRG Oncology and The Central Illinois CCOP Heartland NCORP, Decatur, IL; NRG Oncology and The University of Pittsburgh/Magee Womens Hospital, Pittsburgh, PA; NRG Oncology and The Allegheny Health Network, Pittsburgh, PA; NRG Oncology and The Jewish General Hospital, McGill University, Montréal, QC, Canada; NRG Oncology and The MedStar Franklin Square Medical Center/Harry and Jeanette Weinberg Cancer Institute, Baltimore, MD; NRG Oncology and The University of California Los Angeles, Schools of Medicine and Public Health, Los Angeles, CA; Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, CA.
Thomas B JulianNRG Oncology and The University of Pittsburgh, Pittsburgh, PA; Center for Healthcare Policy and Research, University of California Davis, Sacramento, CA; Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD; NRG Oncology and The Washington Cancer Institute at Washington Hospital Center, Washington, DC and current: Georgetown University, Washington, DC; NRG Oncology and The Colorado Cancer Research Program, Denver, CO; NRG Oncology and Kaiser Permanente, Northern California, Vallejo, CA; NRG Oncology and The Central Illinois CCOP Heartland NCORP, Decatur, IL; NRG Oncology and The University of Pittsburgh/Magee Womens Hospital, Pittsburgh, PA; NRG Oncology and The Allegheny Health Network, Pittsburgh, PA; NRG Oncology and The Jewish General Hospital, McGill University, Montréal, QC, Canada; NRG Oncology and The MedStar Franklin Square Medical Center/Harry and Jeanette Weinberg Cancer Institute, Baltimore, MD; NRG Oncology and The University of California Los Angeles, Schools of Medicine and Public Health, Los Angeles, CA; Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, CA.
Richard G MargoleseNRG Oncology and The University of Pittsburgh, Pittsburgh, PA; Center for Healthcare Policy and Research, University of California Davis, Sacramento, CA; Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD; NRG Oncology and The Washington Cancer Institute at Washington Hospital Center, Washington, DC and current: Georgetown University, Washington, DC; NRG Oncology and The Colorado Cancer Research Program, Denver, CO; NRG Oncology and Kaiser Permanente, Northern California, Vallejo, CA; NRG Oncology and The Central Illinois CCOP Heartland NCORP, Decatur, IL; NRG Oncology and The University of Pittsburgh/Magee Womens Hospital, Pittsburgh, PA; NRG Oncology and The Allegheny Health Network, Pittsburgh, PA; NRG Oncology and The Jewish General Hospital, McGill University, Montréal, QC, Canada; NRG Oncology and The MedStar Franklin Square Medical Center/Harry and Jeanette Weinberg Cancer Institute, Baltimore, MD; NRG Oncology and The University of California Los Angeles, Schools of Medicine and Public Health, Los Angeles, CA; Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, CA.
Edward C McCarronNRG Oncology and The University of Pittsburgh, Pittsburgh, PA; Center for Healthcare Policy and Research, University of California Davis, Sacramento, CA; Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD; NRG Oncology and The Washington Cancer Institute at Washington Hospital Center, Washington, DC and current: Georgetown University, Washington, DC; NRG Oncology and The Colorado Cancer Research Program, Denver, CO; NRG Oncology and Kaiser Permanente, Northern California, Vallejo, CA; NRG Oncology and The Central Illinois CCOP Heartland NCORP, Decatur, IL; NRG Oncology and The University of Pittsburgh/Magee Womens Hospital, Pittsburgh, PA; NRG Oncology and The Allegheny Health Network, Pittsburgh, PA; NRG Oncology and The Jewish General Hospital, McGill University, Montréal, QC, Canada; NRG Oncology and The MedStar Franklin Square Medical Center/Harry and Jeanette Weinberg Cancer Institute, Baltimore, MD; NRG Oncology and The University of California Los Angeles, Schools of Medicine and Public Health, Los Angeles, CA; Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, CA.
Patricia A GanzNRG Oncology and The University of Pittsburgh, Pittsburgh, PA; Center for Healthcare Policy and Research, University of California Davis, Sacramento, CA; Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD; NRG Oncology and The Washington Cancer Institute at Washington Hospital Center, Washington, DC and current: Georgetown University, Washington, DC; NRG Oncology and The Colorado Cancer Research Program, Denver, CO; NRG Oncology and Kaiser Permanente, Northern California, Vallejo, CA; NRG Oncology and The Central Illinois CCOP Heartland NCORP, Decatur, IL; NRG Oncology and The University of Pittsburgh/Magee Womens Hospital, Pittsburgh, PA; NRG Oncology and The Allegheny Health Network, Pittsburgh, PA; NRG Oncology and The Jewish General Hospital, McGill University, Montréal, QC, Canada; NRG Oncology and The MedStar Franklin Square Medical Center/Harry and Jeanette Weinberg Cancer Institute, Baltimore, MD; NRG Oncology and The University of California Los Angeles, Schools of Medicine and Public Health, Los Angeles, CA; Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, CA.
NRG Oncology · USGeorgetown University · USHarry and Jeanette Weinberg Foundation · USKaiser Permanente Vallejo Medical Center · USMagee-Womens Hospital · USMcGill University · CANational Cancer Institute · USUCLA Jonsson Comprehensive Cancer CenterUniversity of California, Davis · USUniversity of Pittsburgh · US
Funding
NRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8MStatistics CoreU10CA180822 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI James J. Dignam, GREG YOTHERS · 2014 to 2026
$146.4MNRG Oncology NCORP Research Base-BIQSFPUG1CA189867 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Deborah Watkins Bruner, Lisa A. Kachnic · 2014 to 2026
$140.5MNCI NIH HHS U10 CA180822NCI NIH HHS U10 CA180868NCI NIH HHS UG1 CA189867
Abstract
Background: The long-term effects of chemotherapy are sparsely reported. Peripheral neuropathy (PN) is one of the most frequent toxicities associated with taxane use for the treatment of early-stage breast cancer. We investigated the impact of the three different docetaxel-based regimens and patient characteristics on long-term, patient-reported outcomes of PN and the impact of PN on long-term quality of life (QOL). Methods: The National Surgical Adjuvant Breast and Bowel Project Protocol B-30 was a randomized trial comparing sequential doxorubicin (A) and cyclophosphamide (C) followed by docetaxel (T) (AC→T), concurrent ACT, or AT in women with node-positive, early-stage breast cancer. The AC→T group had a higher cumulative dose of T. PN was one of the symptoms assessed in a QOL substudy. Statistical methods included simple and mixed ordinal logistic regression and general linear models. All statistical tests were two-sided. Results: Of 1512 patients, 41.9% reported PN two years after treatment initiation. Treatment with AT and ACT was associated with less severe long-term PN compared with AC→T (odds ratio [OR] = 0.45, 95% confidence interval [CI] = 0.35 to 0.58; OR = 0.59, 95% CI = 0.46 to 0.75). Preexisting PN, older age, obesity, mastectomy, and greater number of positive nodes were also associated with higher risk of long-term PN. Patients who reported worse PN symptoms at 24 months had statistically significantly worse QOL (Ptrend < .001). Conclusions: The administration of docetaxel is associated with long-term PN. The lower rate of long-term PN in AT and ACT patients might be an important consideration in supporting choosing these therapies for individuals with preexisting neuropathic symptoms or other risk factors for neuropathy.
Indexed as
Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsChemotherapy, AdjuvantCyclophosphamideDocetaxelDoxorubicinDrug Administration ScheduleFemaleHumansMiddle AgedPeripheral Nervous System DiseasesQuality of LifeTaxoidsCyclophosphamideDocetaxelDoxorubicinTaxoids
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT04558034ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.